07:30 AM EDT, 10/02/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Wednesday that the first participant has been enrolled in a phase 1 trial evaluating BCX17725 to treat patients with Netherton syndrome, a rare, lifelong genetic disorder affecting the skin, hair and immune system.

The trial will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of the drug candidate.

The company said it expects to report initial results from the trial by the end of 2025.